Development of epigenetic-based therapies for PDAC (P13)

• Subject Area: Gastroenterology
• Term: from 2018 to 2023
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 329628492

The epigenetic machinery is contributing to multiple aspects of the disease ranging from tumor initiation to metastasis and therapy resistance. Drugs targeting the epigenetic machinery have entered clinical testing. Our data show that the histone deacetylase inhibitor Panobinostat is highly efficient in an aggressive subtype of the disease. Therefore, we aim to comprehensively understand Panobinostat sensitivity and will develop mechanism-based Panobinostat-anchored combination therapies. In addition, we aim to systematically decipher the contribution of epigenetic mechanisms to therapy resistance, which is a major clinical problem.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1321: Modelling and Targeting Pancreatic Cancer
• Applicant Institution: Technische Universität München (TUM)
• Project Heads: Professor Dr. Günter Schneider; Professor Dr. Gunnar Schotta